Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Validating ctDNA-based approaches in clinical trials

Marla Lipsyc-Sharf, MD, Dana-Farber Cancer Institute, Boston, MA, talks on key challenges associated with the implementation of circulating tumor DNA (ctDNA) and liquid biopsy approaches in clinical practice. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.